Molecular Mechanisms and Targeted Therapies for Colorectal Cancer PDF Download

Author: Shilpa S. Dhar
Publisher: Frontiers Media SA
ISBN: 2832506410
Category : Medical
Languages : en
Pages : 201

View

Book Description

Author: Benjamin Bonavida
Publisher: Springer Science & Business Media
ISBN: 1461470706
Category : Medical
Languages : en
Pages : 271

View

Book Description
​​​​​This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order to develop new drugs that target these resistance factors and such new drugs may either be selective or common to various cancers. If successful, new drugs may not be toxic and may be used effectively in combination with subtoxic conventional drugs to achieve synergy and to reverse tumor cell resistance. The research developments presented in this book can be translated to produce better clinical responses to resistant tumors.

Author: Donatella Delle Cave
Publisher: Mdpi AG
ISBN: 9783036565477
Category : Science
Languages : en
Pages : 0

View

Book Description
Colorectal cancer (CRC) is currently the third leading cause of cancer-related mortality, with 1.9 million incidence cases and 0.9 million deaths worldwide. The global number of new CRC cases is predicted to reach 3.2 million in 2040, based on the projection of aging, population growth, and human development. In clinics, despite advances of diagnosis and surgical procedures, 20% of the patients with CRC present with metastasis at the time of diagnosis, caused by residual tumor cells that have spread to distant organs prior to surgery, affecting the patient survival rate. Standard systemic chemotherapy, alternative therapies that target mechanisms involved in cancer progression and metastasis, immunotherapy, and combination therapies are the major CRC-treatment strategies. In the advanced stage of CRC the transforming growth factor-beta (TGF-β) plays an oncogenic role by promoting cancer cell proliferation, cancer cell self-renewal, epithelial-to-mesenchymal transition, invasion, tumor progression, metastatic spread, and immune escape. Furthermore, high levels of TGF-β1 confers poor prognosis and is associated with early recurrence after surgery, resistance to chemo- or immunotherapy, and shorter survival. Based on the body of experimental evidence indicating that TGF-β signaling has the potential to be a good therapeutic target in CRC, several anti-TGF-β drugs have been investigated in cancer clinical trials. Here, we presented a comprehensive collection of manuscripts regarding studies on targeting the TGF-β signaling in CRC to improve patient's prognosis and personalized treatments.

Author: Chi Hin Cho
Publisher: Academic Press
ISBN: 0128199385
Category : Science
Languages : en
Pages : 242

View

Book Description
Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. Presents a systemic summary of molecular mechanisms for a quick and in-depth understanding Updates current trends in the field with pioneering information on drug resistance Encompasses both basic and clinical approaches for a better understanding of unsolved problems from a holistic point-of-view

Author: Donatella Delle Cave
Publisher:
ISBN: 9783725809516
Category : Medical
Languages : en
Pages : 0

View

Book Description
Colorectal cancer (CRC) is currently the third leading cause of cancer-related mortality. Transforming growth factor beta (TGF-β) signaling has been associated with CRC growth and metastasis due to its involvement in proliferation, epithelial-to-mesenchymal transition (EMT), and angiogenesis. The TGF-β superfamily contains over forty members, including TGF-βs, Nodal, Activin, and bone morphogenetic proteins (BMPs). Three types of TGF-β receptors (TGFβRs) have been identified: types 1, 2, and 3. After ligand binding, TGF-βR2 recruits and phosphorylates TGF-βR1, which, in turn, phosphorylates downstream SMAD (small mother against decapentaplegic) proteins. Phosphorylated SMAD4 translocates into the nucleus, where it activates the transcription of numerous target genes (including SERPINE1, LTBP2, CDKN1A, ARID3B, ATXN1, PTPRK, RAB6A, SMAD7, EHBP1, etc.), acting predominantly as a tumor suppressor gene. Interestingly, alterations in SMAD4 are frequent in metastatic CRC and, together with TGF-βR2 gene mutations, have been reported as late events able to promote CRC progression. The study of the TGF-β pathway in metastatic CRC is challenging because of the great genetic heterogeneity of CRC. However, the increasing availability of targeted and whole-exome DNA sequencing techniques makes it possible to identify genetic mutations in complex, dynamic, and heterogeneous clinical contexts and make correlations with clinical outcomes.

Author: Francis S. Markland
Publisher: John Wiley & Sons
ISBN: 3527320911
Category : Science
Languages : en
Pages : 353

View

Book Description
Themen dieses Bandes sind die molekularen Mechanismen der Tumor-Angiogenese, die Suche nach einschlägigen Targets für die Wirkstoffforschung und die Entwicklung von Kombinationstherapien mit bereits existierenden Ansätzen. Die ideale Informationsquelle für Studenten, Ärzte und Forscher in der Pharmaindustrie!

Author: Kevin M. Haigis, Ph.D.
Publisher: Springer Science & Business Media
ISBN: 146148412X
Category : Medical
Languages : en
Pages : 319

View

Book Description
Colorectal cancer has for more than two decades served as the paradigm for the multi-step concept of cancer initiation and progression. Perhaps more than any other organ site, cancer of the colon is extensively characterized at the molecular level. We are now entering a time when molecular classification, rather than histologic classification, of cancer subtypes is driving the development of clinical trials with emerging targeted therapies. The book will focus on the progression from the identification of mutations that drive colorectal cancer initiation and progression to the search for novel therapies to treat the disease.

Author: María Jesús Fernández Aceñero
Publisher:
ISBN: 9783725804276
Category : Medical
Languages : en
Pages : 0

View

Book Description
Colorectal cancer (CRC) was one of the first tumors in which the molecular mechanisms of carcinogenesis were investigated and confirmed. We now recognize that tumors appearing identical under microscopic examination exhibit molecular differences, and this explains the diverse patient outcomes commonly encountered in clinical practice. Despite their similar appearance, cancers are inherently distinct. However, even in the era of molecular medicine and targeted therapies, the majority of patients with metastatic CRC ultimately succumb to the disease, experiencing a diminished quality of life and a significant number of years of potential life lost. This is especially true as younger individuals increasingly fall victim to this illness. Much remains to be understood regarding the mechanisms contributing to the carcinogenesis and temporal evolution of CRC. This Special Issue is dedicated to recent research exploring the molecular mechanisms underlying CRC, encompassing multi-omics analyses and environmental interactions with diagnostic, prognostic, or predictive value. A fascinating world is open to research, and we hope to shed further light on the biology of this common yet still lethal tumor. We are delighted to embark on this journey with our colleagues, as today's scientific progress relies on collaboration between clinicians and basic scientists. We hope you enjoy this Special Issue.

Author: Yutaka Shimada
Publisher: Springer
ISBN: 9811064695
Category : Medical
Languages : en
Pages : 161

View

Book Description
This volume focuses on the clinical applications of molecular diagnosis and targeted therapy from the viewpoint of oncologists specializing in specific organs. In addition, it discusses the role of molecular diagnosis and targeted therapy in the course of surgical treatment. Recent, rapid advances in molecular biology have shed new light on the mechanisms of cancer progression, and molecularly targeted drugs have been used to treat a variety of malignant diseases. For the diagnosis and precise treatment of cancer, analysis of the molecular background of the tumor is indispensable. However, there are both tumor-specific and comprehensive mechanisms involved in these processes. Accordingly, a firm grasp of molecular diagnosis and targeted therapies for different tumors is vital for clinicians and basic researchers alike. This book provides essential information and the latest findings on molecular diagnosis and targeted therapy for thoracic and gastrointestinal malignancies. Though primarily intended for clinical and basic oncologists, it also offers a useful guide for clinicians who are interested in this field and are considering getting started in molecular diagnosis and targeted therapy.

Author: Peter Jordan
Publisher: Springer
ISBN: 3030027716
Category : Medical
Languages : en
Pages : 150

View

Book Description
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. Recent years have increased significantly our understanding of the genetic alterations that can underlie CRC, but also unraveled the molecular heterogeneity of the disease. Although a simple correlation between genetic pathways, histopathological features and clinical outcome cannot be established, the heterogeneity of CRC is also an opportunity for the development of targeted therapeutic approaches, able to treat an individual tumor with higher efficiency and less toxic side effects. One CRC subtype is characterized by high mutation rates (MSI-H), DNA methylation changes (CIMP-H), mutation in the BRAF oncogene and occurrence of serrated adenomas in the proximal colon. Other groups prevail in the distal colon and consist of either adenomatous polyps with chromosomal aberrations (CIN) and WNT pathway activation, or carry frequent KRAS mutation and metabolic deregulation, or have strong mesenchymal and infiltrative characteristics. Characterization of driver-mutation events in these CRC subgroups has led to the development of specific drugs targeting, for example, the MAPK pathway, but initial clinical trials have revealed unexpected response rates. The collection of chapters in this volume address the biology of specific CRC subtypes and how these may be targeted to improve precision therapy and clinical benefit for the patients.